LIMINATUS PHARMA, INC. Operating Cash Flow
LIMINATUS PHARMA, INC. (LIMN) reported Operating Cash Flow of -$2.99 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- LIMINATUS PHARMA, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$970.00K.
- LIMINATUS PHARMA, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$2.02M.
- LIMINATUS PHARMA, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$386.85K.
- LIMINATUS PHARMA, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$600.61K.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$970.00K derived: 10-Q 6 month − S-1 3 month · filed 2026-08-14 | -$2.99M 10-Q · filed 2026-08-14 | -$3.37M derived: sum of 3 quarters · filed 2026-08-14 | -$3.97M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | -$2.02M S-1 · filed 2026-06-24 | -$2.40M derived: sum of 2 quarters · filed 2026-06-24 | -$3.00M derived: sum of 3 quarters · filed 2026-06-24 | -$11.82M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | -$386.85K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | -$987.46K derived: sum of 2 quarters · filed 2026-06-24 | -$9.80M derived: sum of 3 quarters · filed 2026-08-14 | -$9.96M S-1 · filed 2026-06-24 | |
| 2025-09-30 | -$600.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$9.42M derived: sum of 2 quarters · filed 2026-08-14 | -$9.58M 10-Q · filed 2025-11-14 | -$9.72M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | -$8.82M derived: 10-Q 6 month − S-1 3 month · filed 2026-08-14 | -$8.98M 10-Q · filed 2026-08-14 | -$9.12M derived: sum of 3 quarters · filed 2026-08-14 | -$9.32M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | -$159.39K S-1 · filed 2026-06-24 | $0.00 10-Q · filed 2025-06-02 | -$300.05K derived: sum of 2 quarters · filed 2026-06-24 | -$506.17K derived: sum of 3 quarters · filed 2026-06-24 | -$1.61M derived: sum of 4 quarters · filed 2026-06-24 |
| 2024-12-31 | -$140.66K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | -$346.78K derived: sum of 2 quarters · filed 2026-06-24 | -$1.45M derived: sum of 3 quarters · filed 2026-06-24 | -$1.45M S-1 · filed 2026-06-24 | |
| 2024-09-30 | -$206.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$1.31M derived: sum of 2 quarters · filed 2025-11-14 | -$1.31M 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | -$1.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-10-06 | -$1.10M 10-Q · filed 2025-10-06 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-06-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |